3
0This research presents a longitudinal pan-cancer atlas that maps the dynamic evolution of the tumor immune microenvironment (TIME) during checkpoint inhibitor therapy. By analyzing single-cell data from hundreds of patients, the authors identified four distinct immune states that are conserved across different types of malignancies. Their findings reveal that the direction of microenvironmental remodeling during treatment is a more accurate predictor of clinical success than the tumor's initial pre-treatment state. Specifically, transitions toward B cell-enriched or inflamed states correlate with positive outcomes, while shifts toward myeloid dominance signal therapeutic resistance. To translate these insights into clinical practice, the researchers developed a 59-gene signature capable of forecasting patient response and survival. This work reframes the understanding of immunotherapy by viewing the immune landscape as a dynamic system rather than a static baseline trait.
References:
Lin Z, Chandra M, Srinivas N, et al. Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy[J]. Cancer cell, 2026.
